Founded in Norway in 2014, SPM is a rapidly growing OTC company with full pharmaceutical infrastructure and distribution coverage across the Nordics. The Company enjoys a leading position within the fast-growing sleep and anxiety category, with well-established brands such as Lunixen and Sedix, as well as other products based on the substance melatonin. SPM is a well-resourced platform with c. 15 FTEs, providing broad in-house pharmaceutical competence and experience that will serve as an attractive foundation for Mallax. Furthermore, the Company has a large and steadily increasing pipeline of new products that will be launched over the coming years.
Mallax was founded in 2020 by Impilo, the Nordic healthcare focused investment company, and Anders Larnholt, an experienced pharma and healthcare executive, with the long-term ambition to create a large and well-diversified platform with established pharmaceuticals and OTC products for customers and patients across Europe.
Read moreNews
KKR and Impilo announce strategic partnership together with management in rare disease platform Immedica Pharma
Stockholm and London, 23 April 2024 – Investment funds managed by KKR, a leading global investment firm, have agreed to acquire Immedica Pharma, a pharmaceutical company headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care products. Existing owner, Nordic healthcare investment firm Impilo, will reinvest to become an equal owner alongside KKR. The transaction is subject to customary regulatory and closing conditions.
Impilo invests in Avia Pharma – a leading OTC and Rx pharmaceutical platform
Impilo has closed its investment in Avia Pharma Holding AB, a Sweden-based OTC and Rx pharmaceutical company with presence in the Nordics and Germany. Impilo now partners with two of the co-founders and management of Avia. Our ambition is to build a leading Northern European OTC / Rx platform through organic and inorganic growth.
Loargys® (pegzilarginase) approved in the EU for treatment of arginase 1 deficiency (ARG1-D)
Immedica today announces that the European Commission has granted marketing authorization of Loargys® (pegzilarginase) for the treatment of arginase 1 deficiency (ARG1-D), also known as hyperargininemia, in adults, adolescents and children aged 2 years and older. The approval follows the positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use on October 12.